

Insulin-Dependent Diabetes Mellitus Type 1 Is Potentially Reversible, a Case Report

Hosein Najafpour¹ & Bahram Alamdary Badlou^{2*}

¹SONAPS Clinic. Research and Development Dept., Tehran, Iran

²BBAdvies and Research, Research and Development Dept., Zeist, The Netherlands

***Correspondence to:** Dr. Bahram Alamdary Badlou, BBAdvies and Research, Research and Development Dept., Zeist, The Netherlands.

Copyright

© 2021 Dr. Bahram Alamdary Badlou, *et al.* This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: 27 November 2021 Published: 10 December 2021

Keywords: Diabetes Mellitus; Insulin; Metabolism

History

Here we report an exceptional case of a Persian young man 14 years old Mr. Ali.T who under sudden distress, Erythrocytosis (fig 1), increased HbA1C and glucose levels in the last three months (fig 1,2), possible H. Pylori infection and inflammation but normal fatty acids, Triglyceride, and Cholesterol levels (fig 3), got Diabetes Mellitus type 1 (DMT1) diagnosis (fig 1-3) and insulin-dependent treatments with 2 insulin injections subcutaneous daily (60 injections per month) with some symptomatic food allergies, visit our practice in May 2020, in Tehran, Iran.

Hematology						
Test	Result		Unit	Reference Intervals	Differential	
CBC-diff			and the second second			
W.B.C	5550		x Million/L	4000 - 11000	Neutrophils	44.8 %
R.B.C	\$5.43		x Millions/uL	45.53	Lymphocytes.	44.3 %
Hemoglobia	15.2		g/dL	12.8 - 16.0	Monocytes.	8.3 %
Hematocrit	44.2		5	37.3 - 47.3	Eosinophils.	2.2 %
M.C.V	81.4		n.	81.4 - 91.9	Basophils.	0.4 %
M.C.H	28.0		PS	25.0 - 35.0	Daropinis.	
M.C.H.C	34.4		76	31.0 - 37.5		
Platelets	151		x1000/mm*3	150 - 450		
RDW (C.V)	12.4		%	11.6-14.6		
Neutrophil count	2486		a Million/L	1800 - 8000		
Lymphocyte count	2459		x Million/L	1200 - 5200		
Monocyte count	461		x Million/L	0 - 800		
Eosinophil count	122		x Million/L	0 - 500		
Basophil count	22		x Million/L	0 - 200		
Hematology(2) Test		Result	Unit	Reference Inter	wate	
Test E.S.R (Lst hr.)		<u>Result</u> 5	<u>Unit</u> mm/hr	<u>Reference Inter</u> Ø - 15	valy	
Test E.S.R (1.st hr.)					vals	
<u>Test</u> E.S.R (Lst hr.) Checked by المحري (Checked by المحري) Biochemistery				0 - 15		
<u>Test</u> E.S.R (Lst hr.) Checked by المحري المحري Biochemistery Test		5	mm/hr <u>Unit</u>			
Test E.S.R (Lst hr.) Checked by Subsects 5 Biochemistery Test Fasting Blood Sugar		5 <u>Result</u>	mm/hr <u>Unit</u> mg/dL	0 - 15 <u>Reference Inter</u> 60 - 100		
Test E.S.R (Lst hr.) Checked by Solwards, Biochemistery Test Fasting Blood Sugar BUN		5 <u>Result</u> 121*	mm/hr <u>Unit</u> mg/dL mg/dL	0 - 15 <u>Reference Inter</u> 60 - 100 5 - 20		
Test E.S.R (Lst hr.) Checked by Solwards, Biochemistery Test Fasting Blood Sugar BUN		5 <u>Result</u> 121* 10	mm/hr <u>Unit</u> mg/dL	0 - 15 <u>Reference Inter</u> 60 - 100 5 - 20 0.5 - 0.9		
Test E.S.R (Lst hr.) Checked by Solars, 5, Biochemistery Test Fasting Blood Sugar BUN Creatinine		5 <u>Result</u> 121* 10 0.8	mm/hr <u>Unit</u> mg/dL mg/dL mg/dL	0 - 15 <u>Reference Inter</u> 60 - 100 5 - 20 0.5 - 0.9 10 - 20 /To determine n	vals ormal range for <2	or of age
Test E.S.R (Lst hr.) Checked by Judie (3,5) Biochemistery Est Fasting Blood Sugar BUN Creatinine BUN/Cr ratio		5 <u>Result</u> 121* 10 0.8 13	mm/hr <u>Unit</u> mg/dL mg/dL mg/dL	0 - 15 <u>Reference Inter</u> 60 - 100 5 - 20 0.5 - 0.9 10 - 20 /To determine n	ormal range for < 2 ; Vietson pediatric ' s to 129	wr of age

Figure 1: Serology, immunology, and hormone analysis tests showed potentially diabetes indications with an increase in fasting Glucose level, RBCs count but WBC, Hb, HCT, MCV, MCH, MCHC, platelets count, RDW, neutrophils count, lymphocytes, monocytes, eosinophils, basophils count were normal. Simultaneously the ESR, BUN, creatinine, Cholesterol, triglyceride levels were normal.

Biochemistery	-		Reference Between
Test	Result	Unit	Reference Intervals
H.D.L. Cholesterol	\$7	mg/dL	Low: <40 Acceptable: >45
L.D.L-Cholesterol	**	mg dL	Acceptable: <110 Borderline: 110-129 High: = or > 130
Non-HDL Cholesterole	95	mg'dl.	Acceptable: <120 Borderline-high: 120-144 High: = or > 145
Calcium	9.4	mg/dL	8.4 - 10.5
Phosphorus	4.5	mg/dL	2.99 - 5.47
S.G.O.T (AST)	23	UL	7.43
S.G.P.T (ALT)	20	U/L	4-39
Alkaline Phosphatase	847	U/L	15 years: 367-1359 16 years: 271-1109
Three-months' avera	ge blood	l glucose s	tate
Test	Result	Unit	Reference Intervals
Hb Ale (By gold-standard	7.7	76	Non-diabetics: 4-5.6
HPLC method)			Therapeutic goals for diabetics: <7.5
HPLC method) Estimated Average Glucose (eAG) 4	174	mg'dL	Non-diabetics: 70-115 Therapeutic goals for diabetics: 70-168
HD AAc (Dy HPLC); Homeyfoliun AAc eriteri HD AAc can be fabely logh in aron, detficie HD AAc can be fabely low in some conditio	a for diagnosing ncy anemia, and	diabetes have not bee some HD variants,	Non-diabetics: 70-115
Estimated Average Glucose (eAG) 4 IIB AIc (By IIPLC); Homoglobin Aic orders Bb Aic can be fabrily high in ison-defice Bb Aic can be fabrily low in some conditio Checked by Columna, d's	ia for diagnoring, ncy anemia, and na like heavy or c	diabetes have not bee some HD variants,	Non-diabetics: 70-115 Therapeutic goals for diabetics: 70-168 n established for patients who are <3A years of age.
Estimated Average Glacose (eAG) (HB Alc (By HPLC); Homoglobis Alc order Bb Alc can be fabrity high in level, defice the Alc can be fabrity low in some condition the Alc can be fabrity low in some condition	is for diagnoring, may anemia, and as like basisy or a	diabetes have not bee some HD variants, thronic blooding, som	Non-diabetics: 70-115 Therapeutic goals for diabetics: 70-168 at established for patients who are <1A years of age. The HP variants, recent blood transfasion, and hemolytic anomia
Estimated Average Glacose (eAG) (10) Alc (0) 1076(2) Ilomojdobin Alc order 10) Alc can be fabrily high in ison, defice 10) Alc can be fabrily low in some condition 10) Alc can be fabrily low in some co	ia for diagnoring, ncy anemia, and na like heavy or c	diabetes have not bee some HD variants, teronic blooding, som <u>Unit</u>	Non-diabetics: 70-115 Therapeutic goals for diabetics: 70-168 at established for patients who are <1A years of age, the His variants, recent blood transfasion, and hemolytic anomia <u>Reference Intervals</u>
Estimated Average Glucose (eAG) d HD A&c (By HPLC); Homeglobin A&c enter HD ATc can be fabely high in seen-defficie	a for diagnoring may anemia, and as like basey or i Result	diabetes have not bee some HD variants, thronic blooding, som	Non-diabetics: 70-115 Therapeutic goals for diabetics: 70-168 in established for patients who are <1A years of age. in HP variants, recent blood transfasion, and hemolytic anomia

Figure 2: Biochemistry measurements of (non-)HDL and LDL -Cholesterol, calcium, phosphorus, AST/ALT/ Alkaline phosphatase hepatic enzymes activity, vitamin D and fatty acid metabolism were normal. Though, the HbA1C and glucose tests showed increased levels in the last three months.

Tel C. W. 2.5

Ser

H

Test Ann Ab: T.S. Insi C-I Sm Urit Sp Ph

Ph Gh Bil Un Kei

erology				
	Result	Unit	Reference Inte	ervals
reactive protein (CRP)		mg/L	0-6	
reactive prontin (cert	Negative			
right Agg. test	Negative			
ALCO TY South a set o				
nmunology				
,	Result	Unit	Reference Int.	ervals
(IgM)	2.8	IU/mL	0-8	
Pylori IgG (By ELFA)		TV	Negative : < 0.	75
finiting of the second			Equivocal: 0.7 Positive :>1	3-1
		IU/mL	>25 : Atopy	Unlikely
rum IgE	8.8	TOTAL	>100 : Atopy	Probable
د کتربور منالحان (kod by				
ormone Analys	is		1.00	
		Unit	Reference Int	ervals
I THE CONTRACTOR	mal) 0.1	IU/mL	0 - 40	
nti TPO (Anti Microso 18	enary our	10,1110		
S.H (by ECL)	2.7	mIU/L	0.25 - 5.25	
	9_1		6 - 27	
sulia Peptide	1.340	ng/L	900 - 4000	
ched by Julia 12 for	1.010			
curry, Swarthar				
rine Analysis				
croscopic		-11	Microscopic	
ine Analysis			W.B.C.	1-2
olor	Vellow	the second second	RBC	0-1
ppearance	Turbid		Epithelial Cells	1-2
	10.30		Cast	Negative
H	Acid	-	Crystals	Negative
roteins	Negative			
lucose	Negative			
lirubia	Negative			
obilinogen	Negative			
tones	Negative			
lerase	Negative			
base	Negative			

Figure 3: Immunologic analysis showed an increased H. Pylori-IgG but IgE was normal. Besides, the Insulin, C-peptide, and other hormones' levels, serology CRP, and urine analysis were normal.

After our Medical team visited diagnostics and treatments (D&T), we did succeed to change our case's metabolism as such, which our D&Ts caused his whole insulin metabolism was changed, considerably. Our D&Ts previously changed another patient's metabolism and restored her complex cyanotic tetralogy of Fallot [1]. Besides, our case who DMT1 was confirmed, in less than 24 hours become independent of insulins' injections, however. Moreover, we did succeed to decrease his Insulin injections frequency, considerably.

Physical Examinations

A 14-years old Persian young thin man presented with DM1 disorders increased HbA1c and glucose in the last three months' checkups, potential gastrointestinal tracks and hematologic inflammation and H.Pilory chronic infection were generally chronic-related distressed with anxiety for treatments, and with glucoseand, not fatty acids 'metabolic syndrome showed increased systemic HbA1c levels in the last two months. Our SONAPS diagnostic and associated treatments and diet-related approaches showed remarkable signal transduction disorders in the Vagal nervous system associated with central nervous systems (CNS) and (co) related brain-gut-heart axis leakages.

Lesson Learned

Known is that DMT1 is an irreversible metabolic disease, which could potentially progress toward severe insulin-dependent metabolic disorders and an increase in morbidity and mortality rates. The Saliva amylase overproduction (originating from Saliva-Kidney-GIT axis) and associated side effects might chronically result in the DMT1 (ir-)reversibly [1-5]. Where does serum amylase come from? and what is the mechanism of amylase production/recirculation/clearance disorders? are not completely elucidated yet. Moreover, recent data are suggesting that the serum amylase concentration redirects the equilibrium between the rates of amylase entry into-, and removal from the systemic blood circulation [3-5]. The pancreas and salivary glands have amylase concentrations that are several orders of magnitude greater than that of any other normal tissue, and these two organs probably account for almost all of the serum amylase activity in normal persons [4-8].

Recall, the Pancreatic hyperamylasemia might be resulted from an offense to the pancreas, ranging from trivial cannulation of the pancreatic duct to severe pancreatitis [4-8]. Hyperamylasemia due to salivary-type isoamylase is observed in conditions involving the salivary glands, as we also reporting in our case here (fig 4). In addition, this type of hyperamylasemia occurs in conditions, in which there is no clinical evidence of salivary gland diseases, such as chronic alcoholism, postoperative states (particularly postcoronary bypass), lactic acidosis, anorexia nervosa or bulimia, and malignant neoplasms that secrete amylase [4-8]. Hyperamylasemia can also result from decreased metabolic clearance of amylase due to renal failure or macroamylasemia [4-8]. Moreover, in our case Mr. Ali T. now 15 years old showed healthy kidney and glomerular filtrations during last years' checkups.






Figure 4: Saliva proteomics of Mr. Ali T. (our case) compared to 2 different controls, who were used as negative controls for DMT1. Original data and their differences in saliva proteins i.e. Mucin 5, amylase, agglutinin expression are depicted and analyzed.

Taken together, in our case either with combination of our in-house developed SONAPS as described [1], and/or with personalized diagnostics i.e allergic diet restrictions, adjustments of recommended appropriate diet supplements, personalized medical consult: not only significantly decreased the degree of Insulin injections frequency, but also did decrease his distressed condition, remarkably. Although, because of distance and limited access of patient to first degree Medicare and Medicaid he did fall back to insulin-dependent condition again, however. More in detail investigation in near future needed to unravel what we exactly done that made him insulin-independent.

Bibliography

1. Bahram Alamdary Badlou & Hosein Najafpour (2020). Management of platelets in a persian girl with the tetralogy pentalogy of fallot: A Case Report Study. *J Intern Med Emerg Res.*, 1(1), 1-10.

2. Asadifar, Mehrnaz, Mostafa Bakhti, Mehran Habibi-Rezaei, Ali Akbar Moosavi-Movahedi, Tabatabi Mr, Minoo Ahmadinejad & Badlou, B. A. (2015). Platelet aggregation increased by advanced glycated hemoglobin. *Journal of Blood Disorders and Transfusion*, 6(4), 1-6.

3. Bahram Alamdary Badlou (2019). Platelet hyperactivity and dysfunction in diabetes and cancer. *Editorial – Archives of Pharmacology and Therapeutics Editorial*, 1(2), 25-26.

4. Enrique de-Madaria, Keith Siau & Karina Cardenas-Jaen (2021). Increased amylase and lipase in patients with COVID-19 pneumonia: don't blame the pancreas just yet! *Gastroenterology*, *160*(5), 1871-1904.

5. Wang, F., Wang, H., Fan, J., Zhang, Y., Wang, H. & Zhao, Q. (2020). Pancreatic injury patterns in patients with coronavirus disease 19 pneumonia. *Gastroenterology*, *159*(1), 367-370.

6. Pieper-Bigelow, C., Strocchi, A. & Levitt, M. D. (1990). Where does serum amylase come from and where does it go? *Gastroenterol Clin North Am.*, 19(4), 793-810.

7. Berk, J. E., Shimamura, J. & Fridhandler, L. (1978). Amylase changes in disorders of the lung. *Gastroenterology*, 74(6), 1313-1317.

8. Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., *et al.* (2013). Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus. *Gut.*, *62*(1), 102-111.